Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 129 resultados
LastUpdate Última actualización 15/03/2026 [07:13:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 75 a 100 de 129 nextPage  

Detachable detection device and needle assisting device

NºPublicación:  CN121421520A 30/01/2026
Solicitante: 
SHENZHEN MUXIN TECH CO LTD
\u6DF1\u5733\u6728\u82AF\u79D1\u6280\u6709\u9650\u516C\u53F8
CN_121421520_PA

Resumen de: CN121421520A

The embodiment of the invention provides a detachable detection device and a needle assistor, the detection device is used for detecting blood glucose, the detection device comprises a detection assembly, a sensor assembly and a needling assembly, the detection assembly comprises a flat shell, the outer wall of the bottom of the flat shell is sunken inwards to form a containing cavity, the sensor assembly comprises a base and a probe, the base is provided with a second via hole, and the probe is arranged in the containing cavity. The base is detachably clamped in the containing cavity, part of the probe is located in the base, part of the probe extends out of the hole wall of the second through hole and extends towards the side away from the detection assembly, and when the base is located in the containing cavity, the probe is electrically connected with the detection circuit board. According to the embodiment of the invention, the detection assembly and the sensor assembly are mutually detachable and can be clamped, so that only the sensor assembly is sterilized instead of the detection assembly in the sterilization process, and the influence on the detection circuit board in the detection assembly in the electromagnetic wave or irradiation sterilization process can be avoided; the product yield of the detection device is improved.

Non-invasive blood glucose detection device and method based on wavefront plastic subcutaneous focusing

NºPublicación:  CN121421530A 30/01/2026
Solicitante: 
CHANGSHA SIMURUI INFORMATION TECH CO LTD
\u957F\u6C99\u601D\u6728\u9510\u4FE1\u606F\u6280\u672F\u6709\u9650\u516C\u53F8
CN_121421530_PA

Resumen de: CN121421530A

The invention discloses a non-invasive blood glucose detection device and method based on wavefront shaping subcutaneous focusing, and the device comprises a transmitting module which comprises a narrow linewidth pump light source, a locking amplification modulator and a transmitting end spatial light modulator and is used for transmitting pump light modulated by a specific frequency; the receiving module comprises a receiving end spatial light modulator and a light detector and is used for synchronously collecting spectrums, and the light detector comprises a spectrograph or a wavelength selection detector so as to obtain glucose characteristic signals; and the lens group is placed on the skin surface of a testee. The method has the advantages that through double-end cooperative closed-loop control of transmitting end wavefront compensation and receiving end space screening and in combination with a double-criterion positioning mechanism of spectrum attenuation and scattering characteristic change, pump light can be accurately focused and locked in a preferable blood glucose information optical detection space window below the epidermis under the condition of not depending on an expensive OCT module.

BLOOD GLUCOSE MEASUREMENT DEVICE USING PHOTONICS MODULE

NºPublicación:  WO2026024081A1 29/01/2026
Solicitante: 
SAMSUNG ELECTRONICS CO LTD [KR]
HANA OPTRONICS INC [KR]
\uC0BC\uC131\uC804\uC790 \uC8FC\uC2DD\uD68C\uC0AC,
\uD558\uB098\uC635\uD2B8\uB85C\uB2C9\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC
WO_2026024081_PA

Resumen de: WO2026024081A1

According to one embodiment of the present disclosure, an electronic device may comprise: a substrate; a plurality of light sources disposed on the substrate and radiating light of different wavelengths; a temperature sensor disposed close to the plurality of light sources; a wavelength detection circuit electrically connected to at least two light sources among the plurality of light sources; a memory storing instructions; and a processor. The instructions, when executed by the processor, may cause the electronic device to acquire temperature information related to the plurality of light sources by using the temperature sensor. The instructions, when executed by the processor, may cause the electronic device to measure the amount of change in wavelength between the plurality of light sources by using the wavelength detection circuit. The instructions, when executed by the processor, may cause the electronic device to adjust the amount of change in wavelength to be less than or equal to a reference amount of change in wavelength when the amount of change in wavelength according to the acquired temperature information exceeds the reference amount of change in wavelength. The instructions, when executed by the processor, may cause the electronic device to supply a current corresponding to the adjusted amount of change in wavelength to the plurality of light sources. In addition to various embodiments disclosed in the present document, other various embodiments may be possible.

CONTINUOUS ANALYTE MONITORING SYSTEM WITH MICRONEEDLE ARRAY

NºPublicación:  US20260026749A1 29/01/2026
Solicitante: 
BIOLINQ INCORPORATED [US]
Biolinq Incorporated
US_20260026749_PA

Resumen de: US20260026749A1

Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.

MAGNET SYSTEM FOR NUCLEAR MAGNETIC RESONANCE

NºPublicación:  WO2026024763A1 29/01/2026
Solicitante: 
SYNEX MEDICAL INC [CA]
CLOCKER KYLE [US]
SYNEX MEDICAL INC,
CLOCKER, Kyle
WO_2026024763_PA

Resumen de: WO2026024763A1

The system can include: an array of magnets. In variants, the system can function to generate a homogenous magnetic field within a sample (e.g., in the pulp of a finger). In an example, the system can be used for nuclear magnetic resonance (NMR) imaging and/or magnetic resonance imaging (MRI). In a specific example, the system can be used to measure blood analyte levels (e.g., glucose levels) within a sample.

SYSTEMS AND METHODS FOR TITRATING A BASAL INSULIN DOSE AND FOR DETECTING NON-COMPLIANCE WITH DOSE RECOMMENDATIONS

NºPublicación:  WO2026025065A2 29/01/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
ABBOTT DIABETES CARE INC
WO_2026025065_PA

Resumen de: WO2026025065A2

A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.

SYSTEMS AND METHODS FOR PREDICTING BLOOD GLUCOSE

NºPublicación:  WO2026025081A1 29/01/2026
Solicitante: 
CEDARS SINAI MEDICAL CENTER [US]
CEDARS-SINAI MEDICAL CENTER
WO_2026025081_PA

Resumen de: WO2026025081A1

A method for predicting a blood glucose or blood glucose condition in an individual. The method includes receiving, at a current time, data associated with the individual, the data including (i) a set of one or more static data points each being generated or collected at an identical prior point in time occurring before the current time, and (ii) a series of sequential data points, each of the sequential data points being generated or collected within a prior window of time occurring before the current time; inputting the data associated with the individual into a model; and receiving from the model an indication of a risk of the individual developing hypoglycemia within a subsequent window of time after the current time.

DISPOSABLE MULTI-DOSE HIGH-PRECISION INSULIN INJECTION APPARATUS

NºPublicación:  WO2026020518A1 29/01/2026
Solicitante: 
ESC MEDTECH SUZHOU CO LTD [CN]
\u6613\u5B89\u9002\u533B\u7597\u79D1\u6280\uFF08\u82CF\u5DDE\uFF09\u6709\u9650\u516C\u53F8
WO_2026020518_PA

Resumen de: WO2026020518A1

Disclosed is a disposable multi-dose high-precision insulin injection apparatus, comprising a housing, and a dose adjustment unit and an injection transmission unit that are arranged in the housing. The dose adjustment unit is arranged in the upper part in the housing, and the injection transmission unit is arranged in the lower part in the housing. A dose setting unit is in transmission connection with the injection transmission unit. The dose adjustment unit is used for presetting an injection dose, and the injection transmission unit is used for transmitting injection power and discharging the preset injection dose to complete an injection. The disposable multi-dose high-precision insulin injection apparatus described in the present invention uses the dose setting unit to set a dose of insulin to be injected and uses the injection transmission unit to complete the injection of the corresponding dose. The dose setting unit can accurately set a dose to be injected. The apparatus is simple and convenient to operate and cost-effective.

USER PARAMETER DEPENDENT COST FUNCTION FOR PERSONALIZED REDUCTION OF HYPOGLYCEMIA AND/OR HYPERGLYCEMIA IN A CLOSED LOOP ARTIFICIAL PANCREAS SYSTEM

NºPublicación:  US20260027301A1 29/01/2026
Solicitante: 
INSULET CORP [US]
INSULET CORPORATION
US_20260027301_PA

Resumen de: US20260027301A1

Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.

ELECTRONIC DEVICE, AND NON-INVASIVE BLOOD GLUCOSE MEASUREMENT METHOD OF ELECTRONIC DEVICE

NºPublicación:  WO2026023864A1 29/01/2026
Solicitante: 
SAMSUNG ELECTRONICS CO LTD [KR]
HANA OPTRONICS INC [KR]
\uC0BC\uC131\uC804\uC790 \uC8FC\uC2DD\uD68C\uC0AC,
\uD558\uB098\uC635\uD2B8\uB85C\uB2C9\uC2A4 \uC8FC\uC2DD\uD68C\uC0AC
WO_2026023864_PA

Resumen de: WO2026023864A1

In an electronic device and an operation method of the electronic device, according to one embodiment, the electronic device may comprise: a light source unit for generating lights of a plurality of wavelength bands; an optical body for irradiating the lights of the plurality of wavelength bands onto the skin of a user; a light-receiving unit for detecting light obtained by reflecting the lights of the plurality of wavelength bands from the skin of the user; a memory for storing at least one computer program including instructions; and at least one processor. When individually or collectively executed by the at least one processor, the instructions can instruct the electronic device to: acquire the intensity of irradiation light of a specific wavelength band irradiated from the light source unit at the user and the intensity of reflected light obtained by reflecting the irradiation light of the specific wavelength band from the user; calculate the response gain of the irradiation light of the specific wavelength band on the basis of the ratio of the intensity of the irradiation light to the intensity of the reflected light; and identify a blood glucose level corresponding to the calculated response gain by using a blood glucose level database including blood glucose level information corresponding to the response gain of each of irradiation lights of the plurality of wavelength bands.

Medicine injection and disease management systems, devices, and methods

NºPublicación:  AU2026200109A1 29/01/2026
Solicitante: 
BIGFOOT BIOMEDICAL INC
Bigfoot Biomedical, Inc
AU_2026200109_A1

Resumen de: AU2026200109A1

There is disclosed a cap for an insulin pen comprising: one or more sensors adapted to detect a position of a plunger within an insulin pen; and a user interface comprising one or more user-selectable icons or buttons adapted to announce a meal or an intent to have a meal. have a meal. an a n h a v e a m e a l

SYSTEMS AND METHODS FOR TITRATING A BASAL INSULIN DOSE AND FOR DETECTING NON-COMPLIANCE WITH DOSE RECOMMENDATIONS

NºPublicación:  US20260026758A1 29/01/2026
Solicitante: 
ABBOTT DIABETES CARE INC [US]
Abbott Diabetes Care Inc
US_20260026758_PA

Resumen de: US20260026758A1

A system for titrating a basal insulin dose that includes a glucose monitoring device configured to collect glucose data of a user, processors in communication with the glucose monitoring device, and a memory coupled to the processors. The processors are configured to determine an initial basal insulin dose, receive insulin data and glucose data during a titration period. The validity of each day is assessed, and a titration glucose level is determined for each valid day. The titration glucose level for each day is compared to glucose level thresholds, and a recommended adjustment to the basal insulin dose is determined based on the comparison.

SYSTEM FOR DECISION SUPPORT

NºPublicación:  EP4685812A2 28/01/2026
Solicitante: 
DEXCOM INC [US]
DexCom, Inc
EP_4685812_A2

Resumen de: EP4685812A2

Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state.

CONTINUOUS BLOOD SUGAR MEASURING DEVICE

NºPublicación:  HUE073160T2 28/01/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
US_2025352095_PA

Resumen de: US2025352095A1

The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.

CONTINUOUS GLUCOSE MONITORING DEVICE

NºPublicación:  HUE073365T2 28/01/2026
Solicitante: 
I SENS INC [KR]
i-Sens, Inc
US_2025352093_PA

Resumen de: US2025352093A1

The present disclosure relates to a continuous glucose monitoring device. The present disclosure provides a continuous glucose monitoring device wherein: a body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus a user's additional work for attaching the body attachment unit to the body is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by the user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.

BODY ATTACHABLE UNIT FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT

NºPublicación:  US20260020785A1 22/01/2026
Solicitante: 
I SENS INC [KR]
I-SENS, INC
US_20260020785_PA

Resumen de: US20260020785A1

The present disclosure relates to a continuous blood glucose measurement body attachment unit, and provides a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator so as to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip so as to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be more accurately measured.

METHOD FOR MANUFACTURING INSERTION GUIDE NEEDLE FOR CONTINUOUS BLOOD GLUCOSE MONITORING DEVICE

NºPublicación:  US20260020779A1 22/01/2026
Solicitante: 
I SENS INC [KR]
I-SENS, INC
US_20260020779_PA

Resumen de: US20260020779A1

The present disclosure relates to a method for manufacturing an insertion guide needle for a continuous blood glucose monitoring device. The present disclosure provides a method for manufacturing an insertion guide needle for a continuous blood glucose monitoring device, by which: an insertion guide needle can be manufactured through a cutting process and a bending process of a needle raw plate, so that a complicated manufacturing process is unnecessary, and can thus be easily manufactured through a simple process; an enlargement incision part for continuous enlargement and incision, etc. can be conveniently manufactured through such a simple processing process, so that a manufacturing cost thereof can be reduced and also the size accuracy of the insertion guide needle can be improved; and, particularly, in a process of inserting the insertion guide needle into skin, the insertion guide needle can be brought into point contact with the skin to cut the skin, and then can continuously cut the skin in an enlarged manner, so as to minimize pains which may occur in the process of inserting the insertion guide needle into the skin, thereby alleviating the sense of repulsion or tension at the time of using the continuous blood glucose monitoring device.

RAPID DETECTION OF HYPOGLYCEMIA INCIDENCE USING CONTINUOUS GLUCOSE MONITORING

NºPublicación:  US20260020780A1 22/01/2026
Solicitante: 
DEXCOM INC [US]
Dexcom, Inc
US_20260020780_PA

Resumen de: US20260020780A1

Certain aspects of the present disclosure provide systems and techniques for rapid detection of repetitive metabolic events in a host based on measured analyte data provided by an analyte monitor worn by the host. An example system is configured to obtain measured glucose data of the host. A subset of the measured glucose data is determined, based on performing a filtering operation on the measured glucose data. A respective range of a likelihood of an occurrence of a metabolic is determined for each value within the subset of the measured glucose data. For at least one value within the subset of the measured glucose data, a state of the metabolic event is determined based in part on at least one of an upper bound or a lower bound of the respective range corresponding to the at least one value within the subset of the measured glucose data.

MAGNET SYSTEM FOR NUCLEAR MAGNETIC RESONANCE

NºPublicación:  US20260023141A1 22/01/2026
Solicitante: 
SYNEX MEDICAL INC [CA]
Synex Medical Inc
US_20260023141_PA

Resumen de: US20260023141A1

The system can include: an array of magnets. In variants, the system can function to generate a homogenous magnetic field within a sample (e.g., in the pulp of a finger). In an example, the system can be used for nuclear magnetic resonance (NMR) imaging and/or magnetic resonance imaging (MRI). In a specific example, the system can be used to measure blood analyte levels (e.g., glucose levels) within a sample.

IMPROVING AN ACCURACY OF GLUCOSE PREDICTIONS FOR PATIENTS BY FACILITATING SUBMISSION OF CONTEXTUAL DATA

NºPublicación:  WO2026019913A1 22/01/2026
Solicitante: 
DEXCOM INC [US]
DEXCOM, INC
WO_2026019913_PA

Resumen de: WO2026019913A1

In an embodiment, a method includes receiving analyte measurements of a patient for a time period. The method further includes providing, to a user, an interface for supplying contextual data indicative of contextual events for the time period and receiving the contextual data via the provided interface. The method further includes analyzing the analyte measurements and the contextual events to determine a condensed timeline of patient data for the time period, the condensed timeline of patient data including a partial subset of the contextual events. The method further includes presenting information related to the condensed timeline to the patient.

ACTIVITY MONITORING SYSTEMS AND METHODS

NºPublicación:  US20260024646A1 22/01/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
US_20260024646_PA

Resumen de: US20260024646A1

Disclosed herein are techniques related to product consumption recommendations. In some embodiments, the techniques may involve obtaining, for a patient, historical data comprising activity data, food consumption data, and glucose data. The techniques may further involve training a machine learning model to: predict glucose response parameters for the patient using the historical data as a training set; and utilize the predicted glucose response parameters to determine a recommendation associated with consumption of a product by the patient to maintain a glucose level within a target range during an activity.

BLOOD GLUCOSE MEASUREMENT BASED ON RAMAN SPECTROSCOPY

NºPublicación:  AU2024280120A1 22/01/2026
Solicitante: 
APOLLON INC
APOLLON INC
AU_2024280120_PA

Resumen de: AU2024280120A1

Blood glucose level measurement includes a light source configured to irradiate light to a subject; a monochrome part configured to separate wavelength components of the light that is reflected and scattered from the subject; a light receiver configured to receive the light transmitted via the monochrome part and to generate electrical signals based on the received light; and a processor configured to extract information on the blood glucose level of the subject based on a frequency shift of the light due to the Raman effect.

Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

NºPublicación:  US20260022183A1 22/01/2026
Solicitante: 
REGENERON PHARMACEUTICALS INC [US]
Regeneron Pharmaceuticals, Inc
US_20260022183_A1

Resumen de: US20260022183A1

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies

NºPublicación:  US20260022182A1 22/01/2026
Solicitante: 
REGENERON PHARMACEUTICALS INC [US]
Regeneron Pharmaceuticals, Inc
US_20260022182_A1

Resumen de: US20260022182A1

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

MEDICINE INJECTION AND DISEASE MANAGEMENT SYSTEMS, DEVICES AND METHODS

Nº publicación: US20260021256A1 22/01/2026

Solicitante:

BIGFOOT BIOMEDICAL INC [US]
Bigfoot Biomedical, Inc

US_20260021256_PA

Resumen de: US20260021256A1

One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.

traducir